Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: March 21, 2012
Last updated: April 15, 2016
Last verified: April 2016
The study is designed to evaluate the use of ETT ECG indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Condition Intervention Phase
Atherosclerotic Coronary Vascular Disease
Drug: Ranolazine
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Electrocardiogram interval times adjusted for heart rate [ Time Frame: 14 days (+/- 3 days) ]

Secondary Outcome Measures:
  • Exercise Duration [ Time Frame: Baseline, Day 1, and Day 15 ]
  • Time to ischemia [ Time Frame: 14 days (+/-3 days) ]
  • Time to angina [ Time Frame: 14 days (+/-3 days) ]

Enrollment: 11
Study Start Date: March 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Ranolazine bid (twice a day) for 14 days.
Drug: Ranolazine
twice per day for 14 days
Other Name: Ranexa®


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of stable coronary artery disease

Exclusion Criteria:

  • • Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.

    • History of chronic atrial fibrillation.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01562041

United States, Florida
Novartis Investigative Site
Jacksonville, Florida, United States, 32216
United States, New York
Novartis Investigative Site
New York, New York, United States, 10021
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01562041     History of Changes
Other Study ID Numbers: CPJMR0032105
Study First Received: March 21, 2012
Last Updated: April 15, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Cardiovascular disease
Exercise Treadmill Test
Myocardial ischemia

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017